Mitsuya H相关文献与解析，生知库 | 链接生命科学的每一步

Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance

通过基于HIV耐药性的分子、生化和结构特征的合理药物设计来克服HIV耐药性

期刊:Cellular and Molecular Life Sciences

影响因子:6.2

doi:10.1007/s00018-006-6009-7

Yin, P D; Das, D; Mitsuya, H

Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

鉴定出阻断人类免疫缺陷病毒 1 型在 gag-pol 跨框结构域内复制的关键靶序列

期刊:Journal of Virology

影响因子:3.8

doi:10.1128/jvi.74.10.4621-4633.2000

Sei S, Yang Q E, O'Neill D, Yoshimura K, Nagashima K, Mitsuya H

JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1

JE-2147：一种二肽蛋白酶抑制剂 (PI)，可有效抑制多重 PI 耐药的 HIV-1。

期刊:Proceedings of the National Academy of Sciences of the United States of America

影响因子:9.1

doi:10.1073/pnas.96.15.8675

Yoshimura, K; Kato, R; Yusa, K; Kavlick, M F; Maroun, V; Nguyen, A; Mimoto, T; Ueno, T; Shintani, M; Falloon, J; Masur, H; Hayashi, H; Erickson, J; Mitsuya, H

In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues

体外诱导对Z-亚甲基环丙烷核苷类似物磷酸丙氨酸前药产生抗性的1型人类免疫缺陷病毒变异株

期刊:Antimicrobial Agents and Chemotherapy

影响因子:4.5

doi:10.1128/AAC.43.10.2479

Yoshimura, K; Feldman, R; Kodama, E; Kavlick, M F; Qiu, Y L; Zemlicka, J; Mitsuya, H

In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters

Z-和E-亚甲基环丙烷核苷类似物及其磷酸-L-丙氨酸二酯的体外抗人类免疫缺陷病毒活性

期刊:Antimicrobial Agents and Chemotherapy

影响因子:4.5

doi:10.1128/AAC.43.6.1487

Uchida, H; Kodama, E N; Yoshimura, K; Maeda, Y; Kosalaraksa, P; Maroun, V; Qiu, Y L; Zemlicka, J; Mitsuya, H

Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay

在体外竞争性HIV-1复制试验中，多重二脱氧核苷耐药的1型人类免疫缺陷病毒（HIV-1）的相对适应性

期刊:Journal of Virology

影响因子:3.8

doi:10.1128/JVI.73.7.5356-5363.1999

Kosalaraksa, P; Kavlick, M F; Maroun, V; Le, R; Mitsuya, H

Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing

静脉注射给药后，非人灵长类动物血浆和脑脊液中蛋白酶抑制剂KNI-272的药代动力学；静脉注射和口服给药后，人类免疫缺陷病毒感染儿童血浆和脑脊液中蛋白酶抑制剂KNI-272的药代动力学

期刊:Antimicrobial Agents and Chemotherapy

影响因子:4.5

doi:10.1128/AAC.42.7.1815

Mueller, B U; Anderson, B D; Farley, M Q; Murphy, R; Zuckerman, J; Jarosinski, P; Godwin, K; McCully, C L; Mitsuya, H; Pizzo, P A; Balis, F M

Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology

从未成熟的HIV-1病毒颗粒制剂中去除1型人类免疫缺陷病毒（HIV-1）蛋白酶抑制剂不会导致感染性增加或出现成熟形态。

期刊:Antimicrobial Agents and Chemotherapy

影响因子:4.5

doi:10.1128/AAC.41.5.1017

Humphrey, R W; Ohagen, A; Davis, D A; Fukazawa, T; Hayashi, H; Höglund, S; Mitsuya, H; Yarchoan, R

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine

体外诱导对2'-β-氟-2',3'-二脱氧腺苷耐药的1型人类免疫缺陷病毒变异株

期刊:Antimicrobial Agents and Chemotherapy

影响因子:4.5

doi:10.1128/AAC.41.6.1313

Tanaka, M; Srinivas, R V; Ueno, T; Kavlick, M F; Hui, F K; Fridland, A; Driscoll, J S; Mitsuya, H

PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL

PU.1通过直接反式激活TRAIL诱导骨髓瘤细胞凋亡

Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance

通过基于HIV耐药性的分子、生化和结构特征的合理药物设计来克服HIV耐药性

Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

鉴定出阻断人类免疫缺陷病毒 1 型在 gag-pol 跨框结构域内复制的关键靶序列

JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1

JE-2147：一种二肽蛋白酶抑制剂 (PI)，可有效抑制多重 PI 耐药的 HIV-1。

In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues

体外诱导对Z-亚甲基环丙烷核苷类似物磷酸丙氨酸前药产生抗性的1型人类免疫缺陷病毒变异株

In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters

Z-和E-亚甲基环丙烷核苷类似物及其磷酸-L-丙氨酸二酯的体外抗人类免疫缺陷病毒活性

Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay

在体外竞争性HIV-1复制试验中，多重二脱氧核苷耐药的1型人类免疫缺陷病毒（HIV-1）的相对适应性

Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing

静脉注射给药后，非人灵长类动物血浆和脑脊液中蛋白酶抑制剂KNI-272的药代动力学；静脉注射和口服给药后，人类免疫缺陷病毒感染儿童血浆和脑脊液中蛋白酶抑制剂KNI-272的药代动力学

Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology

从未成熟的HIV-1病毒颗粒制剂中去除1型人类免疫缺陷病毒（HIV-1）蛋白酶抑制剂不会导致感染性增加或出现成熟形态。

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine

体外诱导对2'-β-氟-2',3'-二脱氧腺苷耐药的1型人类免疫缺陷病毒变异株